MicroRNAs (miRNAs) influence several biological processes involved in human disease. Biological experiments for verifying the association between miRNA and disease are always costly in terms of both money and time. Although numerous biological experiments have identified multi-types of associations between miRNAs and diseases, existing computational methods are unable to sufficiently mine the knowledge in these associations to predict unknown associations. In this study, we innovatively propose a heterogeneous graph attention network model based on meta-subgraphs (MSHGATMDA) to predict the potential miRNA-disease associations. Firstly, we define five types of meta-subgraph from the known miRNA-disease associations. Then, we use meta-subgraph attention and meta-subgraph semantic attention to extract features of miRNA-disease pairs within and between these five meta-subgraphs, respectively. Finally, we apply a fully-connected layer (FCL) to predict the scores of unknown miRNA-disease associations and cross-entropy loss to train our model end-to-end. To evaluate the effectiveness of MSHGATMDA, we apply five-fold cross-validation to calculate the mean values of evaluation metrics Accuracy, Precision, Recall, and F1-score as 0.8595, 0.8601, 0.8596, and 0.8595, respectively. Experiments show that our model, which primarily utilizes multi-types of miRNAdisease association data, gets the greatest ROC-AUC value of 0.934 when compared to other state-of-the-art approaches. Furthermore, through case studies, we further confirm the effectiveness of MSHGATMDA in predicting unknown diseases.

MicroRNA (miRNA)-disease association (MDA) prediction is critical for disease prevention, diagnosis, and treatment. Traditional MDA wet experiments, on the other hand, are inefficient and costly.Therefore, we proposed a multi-layer collaborative unsupervised training base model called SGAEMDA (Stacked Graph Autoencoder-Based Prediction of Potential miRNA-Disease Associations). First, from the original miRNA and disease data, we defined two types of initial features: similarity features and association features. Second, stacked graph autoencoder is then used to learn unsupervised low-dimensional representations of meaningful higher-order similarity features, and we concatenate the association features with the learned low-dimensional representations to obtain the final miRNA-disease pair features. Finally, we used a multilayer perceptron (MLP) to predict scores for unknown miRNA-disease associations. SGAEMDA achieved a mean area under the ROC curve of 0.9585 and 0.9516 in 5-fold and 10-fold cross-validation, which is significantly higher than the other baseline methods. Furthermore, case studies have shown that SGAEMDA can accurately predict candidate miRNAs for brain, breast, colon, and kidney neoplasms.

Numerous biological studies have shown that considering disease-associated micro RNAs (miRNAs) as potential biomarkers or therapeutic targets offers new avenues for the diagnosis of complex diseases. Computational methods have gradually been introduced to reveal disease-related miRNAs. Considering that previous models have not fused sufficiently diverse similarities, that their inappropriate fusion methods may lead to poor quality of the comprehensive similarity network and that their results are often limited by insufficiently known associations, we propose a computational model called Generative Adversarial Matrix Completion Network based on Multi-source Data Fusion (GAMCNMDF) for miRNA–disease association prediction. We create a diverse network connecting miRNAs and diseases, which is then represented using a matrix. The main task of GAMCNMDF is to complete the matrix and obtain the predicted results. The main innovations of GAMCNMDF are reflected in two aspects: GAMCNMDF integrates diverse data sources and employs a nonlinear fusion approach to update the similarity networks of miRNAs and diseases. Also, some additional information is provided to GAMCNMDF in the form of a ‘hint’ so that GAMCNMDF can work successfully even when complete data are not available. Compared with other methods, the outcomes of 10-fold cross-validation on two distinct databases validate the superior performance of GAMCNMDF with statistically significant results. It is worth mentioning that we apply GAMCNMDF in the identification of underlying small molecule-related miRNAs, yielding outstanding performance results in this specific domain. In addition, two case studies about two important neoplasms show that GAMCNMDF is a promising prediction method.